cabozantinib,atezolizumab
exelixis,roche
['urothelial carcinoma', 'urothelial', 'cosmic-021']
results from cohorts 3, 4, 5 of the cosmic-021 study: cabo + atezo for urothelial carcinoma reduction in tumor vol: c3 - 74%; c4 - 62%; c5 - 63% mpfs: c3 - 5.6 m; c4 - 7.8 m; c5 - 3.0 m mos: c3 - 14.3 m; c4 - 13.5 m; c6 - 8.2 m #asco22 
Uro Onc @GACancerCenter | Res PD & Ronald W. Lewis MD Chair of Uro Educ @mcg_urology | Digital Media Ed @EUplatinum | #mentalhealth research | @urotoday